MetaCap

Cardio Diagnostics (CDIO) vs ImmuCell (ICCC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ImmuCell is the larger company by market cap ($99.3 million vs $4.7 million), about 21.0 times the size. ImmuCell converts more of its revenue into profit, with a net margin of -3.8% versus -43832.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CDIO-18.37%ICCC+12.69%
+20%-0%-20%
Oct 7, 20261 yearNov 20, 2026
CDIO-14.44%ICCC+11.43%
+13%-2%-16%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CDIO versus ICCC key metrics
MetricCDIOICCC
Share price$1.60$10.92
Market cap$4.74M$99.28M
1-day change-3.03%-2.41%
YTD return—+77.56%
1-year return—+133.33%
5-year return—+18.70%
P/E ratio (TTM)—57.47
EPS (TTM)$-2.52$0.19
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$14.82K$27.64M
Revenue growth (YoY)-57.51%+4.34%
Net income (latest FY)$-6.50M$-1.04M
Gross margin—41.40%
Operating margin-43737.46%5.97%
Net margin-43832.49%-3.76%
52-week high$7.91$12.10
52-week low$0.97$4.67
Distance from 52-week high-79.77%-9.75%
Average volume26.91K13.44K
Shares outstanding2.96M9.09M
Employees1573
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ImmuCell is about 21.0 times larger than Cardio Diagnostics by market value ($99.28M vs $4.74M).
  • ImmuCell is more profitable, keeping -3.8 cents of every revenue dollar as net income versus -43832.5 cents for Cardio Diagnostics.
  • ImmuCell grew revenue faster in its latest fiscal year (+4.34% vs -57.51%).

About Cardio Diagnostics

CDIO stock →

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 15 employees

About ImmuCell

ICCC stock →

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 73 employees

CDIO vs ICCC FAQ

Which is bigger, Cardio Diagnostics or ImmuCell?

ImmuCell (ICCC) is larger, with a market capitalization of $99.28M compared with $4.74M for Cardio Diagnostics (CDIO).

Are Cardio Diagnostics and ImmuCell in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons